Mivebresib

• Target :

  Apoptosis|||Epigenetic Reader Domain

• Related Pathways :

  Chromatin/Epigenetic|||Apoptosis

• Purity :

  0.9932

• Bioactivity :

  Mivebresib (ABBV-075), also known as ABBV-075, is a potent BET inhibitor (bromodomain (BRD) -containing protein) with potential antineoplastic activity. Upon administration, the bromodomain inhibitor ABBV-075 binds to the acetyl-lysine binding site in the BRD of certain BRD-containing protein (s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors. Also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins.

• Smiles :

  O(C1=C(C=2C3=C(C(=O)N(C)C2)NC=C3)C=C(NS(CC)(=O)=O)C=C1)C4=C(F)C=C(F)C=C4

• Molecular Formula :

  C22H19F2N3O4S

• Molecular Weight :

  459.47

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  1445993-26-9